[Study of XXXX in pediatrics regarding clinical efficacy and serum levels (author's transl)].

@entity1 @entity1712 @entity526 @entity7551 @entity294 @entity794 @entity5389 @entity4195 @entity281 @entity17444 @entity299 @entity293 @entity30773
Basic and clinical evaluations of @entity17444 were carried out in @entity1 , and the following results were obtained. 1. @entity17444 20 mg/kg was administered to 9 @entity1 with @entity299 for the prophylaxis against @entity281 before undergoing cardiocatheterization and cardioangiography, and serum levels were determined. Peak levels reached after 30 minutes in 4 of the 9 cases, with a mean peak level of 22.5 mcg/ml and after 1 hour in 5 cases, with a mean peak level of 16.2 mcg/ml. Half life was 3.1 hours in the former group in a 6-hour blood sampling (1.04 hours in a 2-hour sampling) while in the latter group it was 1.37 hours. 2. Clinical responses were evaluated in 56 @entity1 comprising 23 cases of @entity7551 , 8 of @entity5389 , 13 of @entity30773 , 10 of @entity293 and 2 of impetigo. Fifty of these cases had excellent and good responses showing a efficacy rate of 89.3%. 3. From 42 of the cases, 43 strains were isolated as causative organisms. Major organisms included 27 strains of @entity4195 , 9 of @entity526 and 3 of @entity794 . As for bacteriological responses, all strains were eradicated. 4. No severe side effects were observed except for @entity294 of 1 cases and @entity1712 of 2 cases. Furthermore, no @entity1 refused to take @entity17444 dry syrup.
